Forbes October 3, 2012
This morning Sarepta Therapeutics put out a press release detailing the results of a drug that actually seems to help boys with muscular dystrophy walk farther on a six minute walk test. The idea that these patients could actually get better is just stunning This is a very big day — and it is so recently that we finally made similar headway against cystic fibrosis with Vertex’s Kalydeco. This really could be shaking up to be an amazing moment in medicine. Can the price of SRPT go to $100 a share, absolutely.